您的位置：
首页
>
农业专利
>
详情页
Pyrazolopiperidine compounds as CCR1 receptor antagonists
专利权人:
Christian Harcken;Brian Nicholas Cook;Darren DiSalvo;Pingrong Liu;Rajashekhar Betageri;John Lord;Can Mao;Hossein Razavi;Daniel Kuzmich
发明人:
Rajashekhar Betageri,Brian Nicholas Cook,Darren DiSalvo,Christian Harcken,Daniel Kuzmich,Pingrong Liu,John Lord,Can Mao,Hossein Razavi
申请号：
US13328199
公开号：
US08546442B2
申请日:
2011.12.16
申请国别(地区):
US
年份:
2013
代理人:
摘要：
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.Also disclosed are methods of making and methods of using same.
来源网站：
中国工程科技知识中心
来源网址：
http://www.ckcest.cn/home/
相关专利
AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
azaindazole compounds as ccr1 receptor antagonists
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
Pyrazole compounds and substituted pyrroles, modulators of the Orphan nuclear receptor ROR gamma； Pharmaceutical Composition and use in the Treatment or prophylaxis of Diseases of the immune system such as rheumatoid arthritis, lupus, multiple sclerosis, COPD, among others. Ace.
Sustained release dosage form comprising ruxolitinib or its Salt, inhibitor of the Janus Kinase (JAK)； and a method for treating a disease associated with the activity of jak as an autoimmune disease, a disorder of the skin Allograft Rejection, Multiple Sclerosis and arthritis Rheumatoid arthritis, among others.
